Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Sees Significant Growth in Short Interest

Posted by Linda Flegge on Jan 12th, 2026

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) was the recipient of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 4,454 shares, a growth of 1,266.3% from the December 15th total of 326 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 825,551 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily trading volume, of 825,551 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Zacks Research cut shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Daiichi Sankyo presently has an average rating of “Moderate Buy”.

Check Out Our Latest Research Report on DSNKY

Daiichi Sankyo Stock Performance

Shares of OTCMKTS DSNKY traded up $0.07 during midday trading on Monday, reaching $23.06. The company’s stock had a trading volume of 501,925 shares, compared to its average volume of 360,220. The stock has a market capitalization of $43.68 billion and a P/E ratio of 21.75. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.31 and a quick ratio of 1.60. The firm has a 50 day moving average price of $22.37 and a 200-day moving average price of $23.72. Daiichi Sankyo has a 12-month low of $20.51 and a 12-month high of $29.68.

Daiichi Sankyo Company Profile

(Get Free Report)

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.